News articles about Alcobra (NASDAQ:ARCT) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alcobra earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.1438775836601 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Alcobra (NASDAQ ARCT) traded down $0.16 during trading on Monday, reaching $9.01. 21,271 shares of the company were exchanged, compared to its average volume of 93,054. Alcobra has a twelve month low of $5.81 and a twelve month high of $18.06.
Several analysts have recently issued reports on ARCT shares. Ladenburg Thalmann Financial Services started coverage on shares of Alcobra in a research report on Wednesday, November 29th. They issued a “buy” rating on the stock. Zacks Investment Research raised shares of Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, October 4th. WBB Securities raised shares of Alcobra from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Monday, October 9th. Finally, Roth Capital lowered shares of Alcobra from a “buy” rating to a “neutral” rating and lowered their price target for the company from $4.00 to $1.00 in a research report on Friday, September 29th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $1.50.
Alcobra Company Profile
Arcturus Therapeutics Ltd, formerly Alcobra Ltd is a Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated delivery system (LUNAR tm) and UNA Oligomer chemistry technologies.The Company is focused on its research and development in therapeutic areas for rare, infectious, fibrotic, and respiratory diseases with unmet medical needs, including rare liver diseases, infectious diseases, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and replicon RNA vaccines.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.